The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study

BACKGROUND: Although recent guidelines recommend that tapering of biologic disease-modifying anti-rheumatic drugs (bDMARDs) can be considered in patients with rheumatoid arthritis (RA), there has been little evidence supporting the strategy during the non-tumor necrosis factor inhibitor treatment. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jun Won, Kim, Min Jung, Kim, Hyoun-Ah, Kim, Jin Hyun, Lee, Eun Bong, Shin, Kichul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860908/
https://www.ncbi.nlm.nih.gov/pubmed/35211491
http://dx.doi.org/10.3389/fmed.2022.839206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860908/
https://www.ncbi.nlm.nih.gov/pubmed/35211491
http://dx.doi.org/10.3389/fmed.2022.839206

Ejemplares similares